Pilot Study to Evaluate Immunopotentiating Effects of Immulina in Elderly Individuals

University of Mississippi Medical Center1 site in 1 country21 target enrollmentApril 2013

ConditionsElderly Immune Senescence

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Elderly Immune Senescence
Sponsor: University of Mississippi Medical Center
Enrollment: 21
Locations: 1
Primary Endpoint: Interferon gamma (IFNg)
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This will be a small study aimed at determining the effects of oral Immulina consumption on the immune system in elderly individuals.

Registry

clinicaltrials.gov

Start Date

April 2013

End Date

September 2014

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

University of Mississippi Medical Center

Responsible Party

Principal Investigator

Gailen D. Marshall

Professor of Medicine and Pediatrics, Vice Chair for Research, Department of Medicine, Director, Division of Clinical Immunology and Allergy, Chief, Laboratory of Behavioral Immunology Research

University of Mississippi Medical Center

Eligibility Criteria

Inclusion Criteria

•Age 60 and older;
•Generally otherwise healthy for age and not taking medications/supplements that could be expected to affect stress responses and/or impact immune parameters (example - systemic steroids, beta blockers, antidepressants, anti-anxiety drugs, Echinacea supplements, ginseng supplements or Spirulina supplements).

Exclusion Criteria

•Inability to comprehend and speak English;
•Any history of major psychological or psychiatric illness (example - dementia, psychotic disorder, acute mania, current substance abuse) that may limit participant cooperation or compromise the integrity of self-reported clinical or psychological data;
•Presence of a confounding underlying systemic illness which could interfere with immunological profiles (example - severe cardiovascular, pulmonary, hepatic, gastrointestinal, renal, neurological, musculoskeletal endocrine , or metabolic systems; other gross physical impairments; or any history of significant convulsive disorder). Specifically, patients with congestive heart failure, recent viral or bacterial illness in the past 3 weeks, chronic kidney disease, thyroid disorder, autoimmune disease will be excluded.